NEWS & EVENTS

Inotrem expands Series B financing to €58 Million with a mix of Equity and Debt, adding new investors Fountain Healthcare Partners, Kreos and Bpifrance

Paris, February 11th, 2020. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and chronic inflammatory syndromes, announced a €5M capital increase financed by Fountain Healthcare Partners, a leading Irish venture capital firm with offices in Dublin and New York. This fundraising brings Inotrem’s Series B financing to a final closing amount of €44 M. In addition, the Company secured a €13 M credit line from Kreos Capital, Europe’s largest provider of specialty finance to growth companies, and a €1 M loan from Bpifrance, France’s public investment bank, bringing the fundraising to a total of €58 M of equity and debt.

Read full article (PDF)

Lorem Nullam dapibus fringilla facilisis mi, Donec velit,